Beam Therapeutics Inc (NASDAQ: BEAM)’s stock price has decreased by -8.77 compared to its previous closing price of 25.54. However, the company has seen a -11.61% decrease in its stock price over the last five trading sessions. zacks.com reported 2025-01-13 that Beam Therapeutics (BEAM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Is It Worth Investing in Beam Therapeutics Inc (NASDAQ: BEAM) Right Now?
BEAM has 36-month beta value of 1.91. Analysts have mixed views on the stock, with 8 analysts rating it as a “buy,” 3 as “overweight,” 8 as “hold,” and 0 as “sell.”
The public float for BEAM is 72.58M, and currently, short sellers hold a 13.54% ratio of that float. The average trading volume of BEAM on January 15, 2025 was 1.20M shares.
BEAM’s Market Performance
BEAM’s stock has seen a -11.61% decrease for the week, with a -19.38% drop in the past month and a -5.74% fall in the past quarter. The volatility ratio for the week is 8.00%, and the volatility levels for the past 30 days are at 6.77% for Beam Therapeutics Inc The simple moving average for the past 20 days is -13.09% for BEAM’s stock, with a -8.14% simple moving average for the past 200 days.
Analysts’ Opinion of BEAM
Many brokerage firms have already submitted their reports for BEAM stocks, with Leerink Partners repeating the rating for BEAM by listing it as a “Outperform.” The predicted price for BEAM in the upcoming period, according to Leerink Partners is $39 based on the research report published on November 06, 2024 of the previous year 2024.
H.C. Wainwright gave a rating of “Buy” to BEAM, setting the target price at $80 in the report published on July 23rd of the previous year.
BEAM Trading at -11.86% from the 50-Day Moving Average
After a stumble in the market that brought BEAM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.93% of loss for the given period.
Volatility was left at 6.77%, however, over the last 30 days, the volatility rate increased by 8.00%, as shares sank -16.96% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.56% upper at present.
During the last 5 trading sessions, BEAM fell by -11.61%, which changed the moving average for the period of 200-days by -31.39% in comparison to the 20-day moving average, which settled at $26.81. In addition, Beam Therapeutics Inc saw -6.05% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BEAM starting from Bellon Christine, who sale 1,241 shares at the price of $24.68 back on Jan 02 ’25. After this action, Bellon Christine now owns 102,968 shares of Beam Therapeutics Inc, valued at $30,628 using the latest closing price.
Cavanagh Bethany J, the SVP, Finance and Treasurer of Beam Therapeutics Inc, sale 1,117 shares at $24.68 during a trade that took place back on Jan 02 ’25, which means that Cavanagh Bethany J is holding 43,814 shares at $27,568 based on the most recent closing price.
Stock Fundamentals for BEAM
Current profitability levels for the company are sitting at:
- -0.52 for the present operating margin
- 0.94 for the gross margin
The net margin for Beam Therapeutics Inc stands at -0.41. The total capital return value is set at -0.18. Equity return is now at value -18.29, with -11.67 for asset returns.
Based on Beam Therapeutics Inc (BEAM), the company’s capital structure generated 0.17 points at debt to capital in total, while cash flow to debt ratio is standing at -0.84. The debt to equity ratio resting at 0.2. The interest coverage ratio of the stock is -6.96.
Currently, EBITDA for the company is -156.47 million with net debt to EBITDA at 0.42. When we switch over and look at the enterprise to sales, we see a ratio of 5.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.69.
Conclusion
To put it simply, Beam Therapeutics Inc (BEAM) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
